Skip to main content

Table 1 PICOS Criteria for Study Selection

From: Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

PICOS Inclusion Criteria Exclusion Criteria
Population Patients with LABC or MBC who had received at least one prior therapy
•. LABC or MBC defined as stage IV, any T, and N, M1a
•. Target populations were HER2-negative or TNBC, but HER2-positive populations were also included
•. Early disease (stage I–III)
•. First-line treatment
Interventions •. Eribulin mesylate (Halaven®)
•. Carboplatin (Paraplatin®)
•. Cisplatin (Platinol®; Platinol®-AQ)
•. Cyclophosphamide (Cytoxan®; Neosar®)
•. Doxorubicin (Adriamycin®; Rubex®)
•. Doxorubicin liposomal (Doxil®)
•. Epirubicin (Ellence®)
•. Capecitabine (Xeloda®)
•. Fluorouracil (Adrucil®)
•. Gemcitabine (Gemzar®)
•. Methotrexate (amethopterin)
•. Docetaxel (Taxotere®)
•. Ixabepilone (Ixempra®)
•. Paclitaxel (Taxol®; Onxal™)
•. Protein-bound paclitaxel (Abraxane®)
•. Vinorelbine (Navelbine®)
Interventions not of interest or administered in combination with interventions of interest
Comparators BSC, placebo, or all therapies listed above as monotherapy or in combination with other treatments for LABC/MBC  
Outcomes •. Efficacy: OS, PFS, response (including ORR, CR, PR, SD, PD)
•. Safety: AEs, SAEs, discontinuation, and death
Studies not reporting any outcomes of interest
Study Design RCTs Observational studies (including but not limited to case controls, prospective and retrospective cohorts, cross-sectional studies, single-arm trials, SLRs, NMAs, dose-escalation studies)
Countries Any NA
  1. Abbreviations: AE Adverse event, BSC Best supportive care, CR Complete response, HER2 Human epidermal growth factor receptor 2, LABC Locally advanced breast cancer, MBC Metastatic breast cancer, NA Not applicable, NMA Network meta-analysis, ORR Objective response rate, OS Overall survival, PD Progressive disease, PFS Progression-free survival, PICOS Population, interventions, comparisons, outcomes, and study design, PR Partial response, RCT Randomized controlled trial, SAE Serious adverse event, SD Stable disease, SLR Systematic literature review, TNBC Triple-negative breast cancer
  2. a Any size, with or without nearby lymph node involvement, spread to distant organs or distal lymph nodes